Frontiers in Endocrinology

Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists

By Syed Arman Rabbani, Mohamed El-Tanani, Ismail I. Matalka, Manfredi Rizzo

Figure 1 from Frontiers in Endocrinology — Figure 1. Rabbani et al.

ReviewInterventions

The paper

Syed Arman Rabbani, Mohamed El-Tanani, Ismail I. Matalka, Manfredi Rizzo

Ras al-Khaimah Medical and Health Sciences University; University of Palermo

Frontiers in Endocrinology, 24 Sep 2026

doi.org/10.3389/fendo.2026.1902185 PubMed 42851902

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk